5-fluorouracil 500mg/10ml 500 mg/10 ml parenteral ordinary infusion vials/bottles
sandoz gmbh, kundl - 5-fluorouracil - parenteral ordinary infusion vials/bottles - 500 mg/10 ml
5-fluorouracil 1000mg/20ml 1000 mg/20 ml parenteral ordinary infusion vials/bottles
sandoz gmbh, kundl - 5-fluorouracil - parenteral ordinary infusion vials/bottles - 1000 mg/20 ml
5-fluorouracil 5*10ml inj
vhb - 5-fluorouracil - inj - 500mg/10ml - 5*10ml
5-fluorouracil amp. inj
vhb - 5-fluorouracil - inj - 250mg/5ml - amp.
fluroxan 500 injection
5-fluorouracil bp 500mg - injection - 5-fluorouracil bp 500mg - fluorouracil
fluracedyl
pharmachemie b.v. - fluorouracil - solution for injection - 50mg/ml
fluracedyl
pharmachemie b.v. - fluorouracil - solution for injection - 50mg/ml
fluracedyl
pharmachemie b.v. - fluorouracil - solution for injection - 50mg/ml
fluracedyl
pharmachemie b.v. - fluorouracil - solution for injection - 50mg/ml
irinotecan teva
abic marketing ltd, israel - irinotecan hydrochloride trihydrate - concentrate for solution for infusion - irinotecan hydrochloride trihydrate 20 mg/ml - irinotecan - * for the treatment of patients with metastatic colorectal cancer: - in combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for metastatic disease. - as a single agent in patients who have failed an established 5-fluorouracil containing treatment regimen. * for the treatment of patients with small cell lung cancer.* for the treatment of patients with gastric cancer.* irinotecan in combination with leucovorin, oxaliplatin and 5-fluorouracil, for the first-line treatment of patients with metastatic pancreatic adenocarcinoma.